Table 1.
Association between p53 immunoreactivity and clinicopathological features.
| Total No. | p53 Immunoreactivity | |||||||
|---|---|---|---|---|---|---|---|---|
| 262 | (100%) | Wild-Type 59 (23%) |
Overexpression 143 (55%) |
Cytoplasmic Expression 10 (4%) |
Complete Loss 50 (19%) |
p-Value | ||
| Sex | 0.49 | a | ||||||
| Male | 139 | [53%] | 36 [61%] | 73 [51%] | 4 [40%] | 26 [52%] | ||
| Female | 123 | [47%] | 23 [39%] | 70 [49%] | 6 [60%] | 24 [48%] | ||
| Age, years (Mean ± S.D.) | 68.6 ± 12.6 | 68.5 ± 14.1 | 68.5 ± 12.0 | 70.8 ± 7.7 | 69.0 ± 12.9 | 0.79 | b | |
| Size, cm (Mean ± S.D.) | 5.0 ± 2.6 | 5.9 ± 2.6 † | 4.9 ± 2.7 | 4.5 ± 1.9 | 4.3 ± 1.8 | 0.0056 | b | |
| Tumor location | 0.10 | c | ||||||
| Right-sided colon | 120 | [46%] | 35 [59%] | 58 [40%] | 2 [20%] | 25 [50%] | ||
| Left-sided colon | 84 | [32%] | 16 [27%] | 51 [36%] | 5 [50%] | 12 [24%] | ||
| Rectum | 58 | [22%] | 8 [14%] | 34 [24%] | 3 [30%] | 13 [26%] | ||
| pT stage | 0.31 | a | ||||||
| pT2 | 36 | [13%] | 8 [14%] | 18 [13%] | 1 [10%] | 9 [18%] | ||
| pT3 | 182 | [70%] | 42 [71%] | 103 [72%] | 9 [90%] | 28 [56%] | ||
| pT4 | 44 | [16%] | 9 [15%] | 22 [15%] | 0 [0%] | 13 [26%] | ||
| Histological differentiation | 0.73 | a | ||||||
| Well to moderately | 235 | [90%] | 51 [86%] | 129 [90%] | 10 [100%] | 45 [90%] | ||
| Poorly | 27 | [10%] | 8 [14%] | 14 [10%] | 0 [0%] | 5 [10%] | ||
| Mucus production | 0.0015 | a | ||||||
| Positive | 14 | [5%] | 9 [15%] †† | 2 [1%] | 0 [0%] | 3 [6%] | ||
| Negative | 248 | [95%] | 50 [85%] | 141 [99%] | 10 [100%] | 47 [94%] | ||
| Lymph node metastasis | 0.19 | a | ||||||
| Positive | 122 | [49%] | 21 [38%] | 67 [51%] | 5 [50%] | 29 [59%] | ||
| Negative | 124 | [51%] | 34 [62%] | 65 [49%] | 5 [50%] | 20 [41%] | ||
| Peritoneal metastasis | a | |||||||
| Positive | 49 | [19%] | 7 [12%] | 32 [22%] | 0 [0%] | 10 [20%] | 0.15 | |
| Negative | 213 | [81%] | 52 [88%] | 111 [78%] | 10 [100%] | 40 [80%] | ||
| Distant organ metastasis | a | |||||||
| Positive | 43 | [16%] | 5 [8%] | 28 [20%] | 0 [0%] | 10 [20%] | 0.11 | |
| Negative | 219 | [84%] | 54 [92%] | 115 [80%] | 10 [100%] | 40 [80%] | ||
| Operation status | 0.23 | a | ||||||
| Complete resection | 230 | [88%] | 56 [95%] | 122 [85%] | 9 [90%] | 43 [86%] | ||
| Incomplete resection | 32 | [12%] | 3 [5%] | 21 [15%] | 1 [10%] | 7 [14%] | ||
| MMR system status | a | |||||||
| Deficient | 30 | [12%] | 19 [32%] ††† | 8 [6%] | 1 [10%] | 2 [4%] | <0.0001 | |
| Preserved | 232 | [88%] | 40 [68%] | 135 [94%] | 9 [90%] | 48 [96%] | ||
a, Fisher’s exact, b, Kruskal–Wallis or c, chi-squared test with post hoc test (Holm) was used to calculate p-values. †: p = 0.030 vs. overexpression, p = 0.0037 vs. complete loss. ††: p = 0.0019 vs. overexpression. †††: p < 0.0001 vs. overexpression or complete loss. Data are shown as the median (25th, 75th percentiles). The Bonferroni-corrected p-value for significance was p ≈ 0.0042 (0.05/12).